Crossmark

The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review

Crossref DOI link: https://doi.org/10.1007/s00415-025-13093-1

Published Online: 2025-05-15

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Freedman, Mark S. https://orcid.org/0000-0003-1255-9701
Abdelhak, Ahmed https://orcid.org/0000-0001-9731-4169
Bhutani, Mohit K. https://orcid.org/0000-0003-4337-4144
Freeman, Jason

Gnanapavan, Sharmilee https://orcid.org/0000-0003-2817-9922
Hussain, Salman https://orcid.org/0000-0002-1691-8428
Madiraju, Sheshank https://orcid.org/0009-0007-5697-1411
Paul, Friedemann https://orcid.org/0000-0002-6378-0070
Funding

Funding for this research was provided by:

Novartis Pharmaceuticals Corporation
License Information

Text and Data Mining valid from 2025-05-15

Version of Record valid from 2025-05-15
More Information

Article History

Received: 18 December 2024

Revised: 7 April 2025

Accepted: 10 April 2025

First Online: 15 May 2025

Declarations

:

: Mark S. Freedman, in the previous 2 years, received research or educational grants from Sanofi-Genzyme Canada; received honoraria or consultation fees from Alexion/AstraZeneca, Biogen Idec, EMD Inc./EMD Serono/Merck Serono, Find Therapeutics, Hoffman La-Roche, Horizon Therapeutics/Amgen, Novartis, Sandoz, Sanofi-Genzyme, Sentrex, and Teva Canada Innovation; was a member of a company advisory board, board of directors, or other similar groups for Alexion/AstraZeneca, Actelion/Janssen (J&J), Atara Biotherapeutics, Bayer Healthcare, Celestra Health, EMD Inc./Merck Serono, Find Therapeutics, Hoffman La-Roche, Neurogenesis, Novartis, Sanofi-Genzyme, and Sentrex, Setpoint Medical; and participated in a speaker’s bureau sponsored by Hoffman La-Roche, Novartis, and EMD Inc. Ahmed Abdelhak received research funding from the German Multiple Sclerosis Society, the Department of Defense, and the UCSF Weill Institute for Neurosciences. He received speaker fees from Roche and consultation fee from Octave Bio. Jason Freeman is an employee of Novartis Pharmaceuticals, USA. Sharmilee Gnanapavan had received consultation fees and grant support from Novartis, Sanofi-Genzyme, Merck and Roche, UK MS Society, NMSS, NIHR, and NHS Digital. Friedemann Paul has no conflict of interest. Sheshank Madiraju, Salman Hussain, and Mohit K. Bhutani are employees of Novartis Healthcare Private Limited, India.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below